American Resources Corp (NASDAQ:AREC) announced Friday that its Audit Committee has dismissed GBQ Partners LLC as the company’s independent registered public accounting firm, effective the same day.

The Denver Nuggets finally announced their acquisition of Jonas Valanciunas, who they received in a trade for Dario Saric. It was a savvy move, as it got the Nuggets off a contract from someone who ...

Intense itching of the upper arms following sun exposure is often dismissed as a harmless skin reaction. However, this may indicate a neuropathic condition. Brachioradial pruritus (BRP) is a rare and ...

Organizations are using generative AI to stay ahead of the competition, but the real advantage lies in harnessing the power of your own data securely and at scale. One of the most exciting new ...

CINCINNATI (Cincinnati Business Courier) - One of Greater Cincinnati’s fastest-growing companies has moved its office to accommodate its rapid expansion. Norwood-based Lynx Specialty moved into the ...

SQL development is evolving fast, and Microsoft.Build.Sql is leading the charge. This next-generation SDK brings flexible project structures, better source control integration, automated build-time ...

The FDA has expanded Pluvicto's indication for PSMA-positive mCRPC patients post-ARPI therapy, delaying taxane-based chemotherapy. Selection for Pluvicto should be based on PSMA expression using ...

Lutetium (177Lu)-rhPSMA-10.1 showed favorable tumor-to-organ radiation dose ratios in mCRPC patients, indicating potential for improved radioligand therapy outcomes. The mean absorbed radiation dose ...

GBQ Partners, a Top 100 Firm based in Columbus, Ohio, acquired hiring platform Talentcrowd in a move to expand its business technology offerings. Processing Content Talentcrowd, also based in Columbus ...

DBeaver is a free, open-source, cross-platform SQL client and database administration tool. It is designed to support a wide variety of SQL and NoSQL databases, including MySQL and PostgreSQL. Its key ...

Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer. Pluvicto™ ...